Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective-Reference-Cited by-同舟云学术

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective

Published:2002-07 Issue:7 Volume:16 Page:1213-1219
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

La Rosée P,O'Dwyer ME,Druker BJ

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402555.pdf

Reference91 articles.

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia N Engl J Med 1999 341: 164–172

2. Nowell PC, Hungerford DA . A minute chromosome in human chronic granulocytic leukemia Science 1960 132: 1497–1501

3. Rowley JD . A new consistent chromosome abnormality in chronic myelogenous leukaemia detected by quinacrine fluorescence and Giemsa staining Nature 1973 243: 290–293

4. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia Blood 2000 96: 3342–3356

5. Thijsen SFT, Schuurhuis GJ, van Oostveen JW, Ossenkoppele GJ . Chronic myeloid leukemia from basics to bedside Leukemia 1999 13: 1646–1674

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia;Cell Death & Disease;2024-08-23

2. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia;2024-02-20

3. Current Trends in Immuno-Oncology;Cardiovascular & Hematological Agents in Medicinal Chemistry;2023-07

4. Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells;IRAN J BASIC MED SCI;2023

5. The nuclear factor-kappa B pathway and response to treatment in breast cancer;Pharmacogenomics;2017-12